EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies

Juan Manuel Carreño iD, Brian Lerman, Gagandeep Singh, Anass Abbad iD, Temima Yellin, Jordan Ehrenhaus, Miriam Fried, Jessica R Nardulli, Hyun Min Kang, Lubbertus C F Mulder, Charles Gleason, Komal Srivastava und 3 weitere

mBio · 09.04.2025 · 16 (4)

DOI: 10.1128/mbio.03607-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 09.04.2025. Verfasst von Juan Manuel Carreño und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Antibodies, Viral, COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, HHS | NIH | National Institute on Drug Abuse (NIDA).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The evolution of the antibody response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is impacted by the nature and number of antigenic exposures. First-generation coronavirus disease 2019 (COVID-19) vaccines encoded an ancestral spike protein. Updated bivalent vaccines and breakthrough infections have shaped the intricate diversity of the polyclonal antibody response and specificity of individual antibody clones. We and others previously showed that bivalent vaccines containing the ancestral and Omicron (BA.5) spikes induce high levels of cross-reactive antibodies but undetectable BA.5-specific antibodies in serum. Here, we assessed sera collected before as well as 1 and 3 months following administration of an updated XBB.1.5 monovalent vaccine to individuals with diverse infection and vaccination histories. Vaccination increased neutralization against recent variants of concern, including HV.1, JN.1, and the vaccine-homologous XBB.1.5. Antibody binding and avidity against ancestral and XBB.1.5 antigens significantly increased after vaccination. However, antibody depletion experiments showed that most of the response was cross-reactive to the ancestral spike, and only low levels of XBB.1.5-specific antibodies to the spike or the receptor-binding domain were detected. Importantly, increased antibody levels were still detectable in circulation 3 months post-vaccination and cross-reacted with severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) as measured by pseudovirus neutralization and binding assays. Overall, our data suggest that the XBB.1.5 monovalent vaccine predominantly elicits a cross-reactive response imprinted by viral spike antigens encountered early during the pandemic. IMPORTANCE Updated COVID-19 vaccine formulations and SARS-CoV-2 exposure history affect the antibody response to SARS-CoV-2. High titers of antibodies are induced in serum by XBB.1.5 monovalent vaccination. Antibody depletion experiments reveal that the majority of the antibody response is cross-reactive to the ancestral spike, despite vaccination increasing neutralization against recently circulating Omicron variants. Vaccine-induced SARS-CoV-2 antibodies cross-react with SARS-CoV-1 and remain in the bloodstream for at least 3 months after immunization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antibodies, ViralCOVID-19 VaccinesCOVID-19HumansCross ReactionsAntibodies, NeutralizingSpike Glycoprotein, CoronavirusFemaleMaleAdultMiddle AgedVaccination

Stichwörter der Autor:innen

COVID-19 vaccineSARS-CoV-2XBB.1.5 monovalent vaccinecross-reactive immune responsesimprinting

Substanzen

Antibodies, ViralCOVID-19 VaccinesAntibodies, NeutralizingSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, USA.
  • The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Juan Manuel Carreño, Anass Abbad, Viviana Simon, Florian Krammer

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • HHS | NIH | National Institute on Drug Abuse (NIDA)
  • NIDA NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • NCATS NIH HHS
  • HHS | NIH | National Center for Advancing Translational Sciences (NCATS)
  • HHS | NIH | National Cancer Institute

Zitieren

APA

Carreño, J. M., Lerman, B., Singh, G., Abbad, A., Yellin, T., Ehrenhaus, J., Fried, M., Nardulli, J. R., Kang, H. M., Mulder, L. C. F., Gleason, C., Srivastava, K., PVI study group, Simon, V., & Krammer, F. (2025). XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies. mBio, 16(4). https://doi.org/10.1128/mbio.03607-24

Vancouver

Carreño JM, Lerman B, Singh G, Abbad A, Yellin T, Ehrenhaus J, et al. XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies. mBio. 2025;16(4). doi:10.1128/mbio.03607-24

BibTeX
@article{Carreo2025,
  author = {Carreño, Juan Manuel and Lerman, Brian and Singh, Gagandeep and Abbad, Anass and Yellin, Temima and Ehrenhaus, Jordan and Fried, Miriam and Nardulli, Jessica R and Kang, Hyun Min and Mulder, Lubbertus C F and Gleason, Charles and Srivastava, Komal and PVI study group, PVI study group and Simon, Viviana and Krammer, Florian},
  title = {XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies},
  journal = {mBio},
  year = {2025},
  volume = {16},
  number = {4},
  doi = {10.1128/mbio.03607-24}
}
Kostenlos starten →